Minnesota Law Brings Transparency to the 340B Drug Pricing Program

This Viewpoint discusses the need for visibility into results of the federal 340B Drug Pricing Program and reviews first data from Minnesota.

from JAMA Health Forum New Online https://ift.tt/SFXgrD0